Table 2 Summary of adverse events in randomized controlled trials included in the meta-analysis
Outcome | Studies | Fibrin sealant events/total | Control events/total | Heterogeneity (P, I2) | Statistical method | Effect estimate | P value |
|---|---|---|---|---|---|---|---|
Any adverse events | 3 | 61/164 | 50/164 | 0.007, 80% | Risk ratio (M-H, fixed, 95% CI) | 1.21 (0.63, 2.31) | 0.57 |
Fever | 3 | 34/164 | 32/164 | 0.94, 0% | Risk ratio (M-H, fixed, 95% CI) | 1.06 (0.79, 1.44) | 0.69 |
Infection | 2 | 3/129 | 2/129 | 0.71, 0% | Risk ratio (M-H, fixed, 95% CI) | 1.50 (0.26, 8.72) | 0.65 |
Hematoma | 2 | 3/60 | 10/63 | 0.90, 0% | Risk ratio (M-H, fixed, 95% CI) | 0.31 (0.09, 1.08) | 0.07 |